SCHEMBL13610956

SCHEMBL13610956

CC(C)(C)OC(=O)N1CC[C@@H](CNC(=O)c2cc(N)c(Cl)c3c2OCCCO3)C(O)C1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.38
PKM P14618 1/20 0.38
DRD2 P14416 4/20 0.38
HTR3E A5X5Y0 1/20 0.38
HTR3B O95264 1/20 0.38
HTR3A P46098 1/20 0.38
HTR4 Q13639 1/20 0.38
HTR3D Q70Z44 1/20 0.38
HTR3C Q8WXA8 1/20 0.38
IL1B P01584 1/20 0.37
P2RX7 Q99572 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
ACKR3 P25106 1/20 0.36
UTS2R Q9UKP6 1/20 0.36
EED O75530 1/20 0.36
RBBP4 Q09028 1/20 0.36
SUZ12 Q15022 1/20 0.36
EZH2 Q15910 1/20 0.36
AEBP2 Q6ZN18 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13603087 1.00 KDM4E (0.38) KDM4EPKMDRD2HTR3EHTR3B
SCHEMBL13603084 0.97 KDM4E (0.39) KDM4EPKMDRD2HTR3EHTR3B
SCHEMBL13610711 0.97 KDM4E (0.39) KDM4EPKMDRD2HTR3EHTR3B
SCHEMBL13600602 0.92 IL1B (0.40) KDM4EPKMDRD2HTR3EHTR3B
SCHEMBL13607394 0.92 IL1B (0.40) KDM4EPKMDRD2HTR3EHTR3B
SCHEMBL13610957 0.90 KDM4E (0.38) KDM4EPKMDRD2HTR3EHTR3B
SCHEMBL13603089 0.90 KDM4E (0.38) KDM4EPKMDRD2HTR3EHTR3B
SCHEMBL13607545 0.87 IL1B (0.39) KDM4EPKMDRD2HTR3EHTR3B
SCHEMBL13600607 0.87 IL1B (0.39) KDM4EPKMDRD2HTR3EHTR3B
SCHEMBL13610955 0.86 KDM4E (0.39) KDM4EPKMDRD2HTR3EHTR3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7638535-B2 (3S)-trans)-8-methyl-3,4-dihydro-2H-benzo[b][1,4]dioxepine-6-carboxylic acid [3-hydroxy-1-(3-methoxy-propyl)-piperidin-4-ylmethyl]-amide; hypermotility, irritable bowel syndrome, constipation or diarrhea predominant IDS, pain and non-pain predominant IBS and bowel hypersensitivity JANSSEN PHARMACEUTICA N.V. (BE) 2009-12-29 US disclosed